研究概要
嵌合抗原受体-自然杀伤(CAR-NK)细胞疗法在治疗血液系统恶性肿瘤方面已显示出良好结果,但对包括胶质母细胞瘤在内的实体瘤疗效有限,部分原因是实体瘤的免疫抑制微环境。
中文摘要
嵌合抗原受体-自然杀伤(CAR-NK)细胞疗法在治疗血液系统恶性肿瘤方面显示出良好效果,但对包括胶质母细胞瘤在内的实体瘤疗效有限,部分原因是实体瘤的免疫抑制微环境。本小型综述聚焦于胶质母细胞瘤微环境为逃避免疫而采用的各种免疫抑制策略,包括基质屏障、缺氧条件、免疫抑制性细胞因子、激活性配体下调以及免疫检查点上调。已提出一系列新兴策略以对抗这些抑制作用,例如对NK细胞进行基因工程改造,以及结合溶瘤病毒疗法对基质进行分子靶向。未来的单细胞时空组学研究有望进一步推动针对胶质母细胞瘤的个性化和动态治疗方法,从而改善预后。
展开英文摘要原文
Chimeric antigen receptor-natural killer (CAR-NK) cell therapy has shown favorable results in treating hematological malignancies but with limited efficacy against solid tumors, including glioblastomas, which is partly due to the immunosuppressive microenvironment of solid tumors. This mini review focuses on the various immunosuppressive strategies employed by the glioblastoma microenvironment for immune evasion, including stromal barriers, hypoxic conditions, immunosuppressive cytokines, downregulation of activating ligands, and upregulation of immune checkpoints. A range of emerging strategies has been proposed to counteract these inhibitory effects, such as genetic engineering of NK cells and molecular targeting of the stroma in combination with oncolytic virus therapy. Future single-cell spatiotemporal omics studies are expected to further enable a personalized and dynamic approach to treating glioblastoma with improved outcomes.
论文信息
- 作者
- Tang E、Chen JY
- 第一作者单位
- North Carolina School of Science and Mathematics, Durham, NC, United States.United States
- 通讯作者单位
- Systems Pharmacology Artificial intelligence (AI) Research Center and Department of Biomedical Informatics and Data Science, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.United Kingdom
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025